Agios' ACTIVATE-Kids trial showed 31.6% of mitapivat-treated children met the hemoglobin response endpoint vs. 0% in the placebo group. Agios reported Q4 Pyrukynd revenue of $10.7M, exceeding the ...

Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety ...

2025 Looking for information on Ioannis Kapodistrias Airport, Kerkyra, Greece? Know about Ioannis Kapodistrias Airport in detail. Find out the location of Ioannis Kapodistrias Airport on Greece map ...

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ story “gaining traction over the next 12 ...

Pelion High School has found its next football coach. Former South Carolina offensive lineman and current Cardinal Newman head coach Cory Helms is the Panthers’ new coach. He replaces Dann ...

Salt Lake City-based Pelion Venture Partners has raised $500 million for a new fund — an unusually large sum for a firm located outside of a coastal hub, and the largest in Utah history.

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of $54.00. The company’s shares ...

In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...

It was the largest protest in Greece in more than a decade and rallies also took place in more than 100 other cities across the country. The protests come following the release to local media of a ...

Feb. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...